Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer

(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized trial...